EEG and ERP Biomarker Assessment for rTMS Treatment Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychiatric and neurological disorders, such as depression and ADHD, have limited effectiveness, necessitating a personalized approach to improve treatment outcomes, particularly in identifying suitable candidates for neuromodulation therapies like rTMS.
Innovation Solution
A method utilizing EEG and ERP data to assess individual susceptibility to neuromodulation treatments by comparing recorded brain activity with reference data, employing specific amplitude and frequency criteria to predict treatment response or non-response, and a device for processing this data to output assessment results.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drug treatments and psychotherapy are applied to treat psychiatric and neurological disorders, then treatment coverage is provided, but effectiveness is limited (40-60% for depression, 60-80% for ADHD)
Solution Approach 1:
The patent applies preliminary action by performing EEG and ERP assessments before treatment to predict treatment response. This pre-assessment allows clinicians to identify which patients are likely to respond to neuromodulation treatments like rTMS, enabling treatment selection before committing to a specific therapy and avoiding ineffective treatments.
Solution Approach 2:
The patent utilizes parameter changes by measuring specific EEG parameters (alpha peak frequency, theta/delta amplitude ratios, P300 amplitude) and ERP parameters to predict treatment response. These physiological parameters serve as biomarkers that change based on individual patient characteristics and predict susceptibility to different treatment modalities.
2Ease of operation
If neuromodulation treatments like rTMS are applied, then localized brain treatment is achieved, but identification of suitable candidates is challenging without reliable predictive methods
Solution Approach 1:
The patent replaces mechanical trial-and-error treatment selection with a physiological measurement system based on EEG and ERP assessments. Instead of attempting multiple treatments to find what works, the system uses objective brain electrical activity measurements to predict treatment response, substituting empirical trial with physiological prediction.
Solution Approach 2:
The patent applies feedback by using baseline EEG and ERP measurements to predict treatment response, creating a feedback loop where pre-treatment physiological data informs treatment selection. This allows clinicians to receive feedback about predicted treatment efficacy before initiating treatment, enabling data-driven treatment decisions.
Data Source
Figure 1
Figure 2
AI summary
Method for assessing the susceptibility of a human individual suffering from a psychiatric or neurological disorder, in particular with depressed mood as a predominant feature, to neuromodulation treatment, in particular repetitive Transcranial Magnetic Stimulation (rTMS), the method comprising: a) Providing a dataset comprising electroencephalographic (EEG) activity and Event Related Potentials (ERP) data of said human individual; b) Assessing the susceptibility of said human individual to neuromodulation treatment based on said dataset.